Stocktoria
Seres Therapeutics, Inc. MCRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-06-26
Seres Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -11910.1% | — | — | -2524.0% | -44.5% |
| Net margin | 721.9% | — | — | -3509.5% | -45.2% |
| FCF margin | 109.6% | — | — | -3347.9% | -2.0% |
| Return on assets | 4.1% | 0.1% | -31.7% | -71.7% | -18.5% |
| Return on equity | 12.9% | 1.0% | 253.5% | -2319.9% | -49.9% |
| Debt / equity | — | — | -2.45× | 4.64× | 0.18× |
| Current ratio | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 |
| Revenue growth | — | — | -100.0% | -95.1% | 336.3% |
Source: SEC EDGAR filings · CIK 0001609809 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.